阅读说明：本技术 口蹄疫病毒样颗粒抗原、及其疫苗组合物、制备方法和应用 (Foot-and-mouth disease virus-like particle antigen, vaccine composition thereof, preparation method and application ) 是由 田克恭 逄文强 肖燕 张许科 于 2020-08-28 设计创作，主要内容包括：本发明提供了A型口蹄疫病毒样颗粒抗原,其由A型口蹄疫病毒流行株VP2、VP3、VP1抗原蛋白组装而成,VP2、VP3、VP1抗原蛋白分别由特定序列的核苷酸序列编码。由该A型口蹄疫病毒样颗粒抗原制备的疫苗,具有针对A型口蹄疫病毒流行株良好的免疫原性。其与O型口蹄疫病毒样颗粒抗原制备的疫苗能分别针对A型口蹄疫病毒流行株、O型口蹄疫病毒进行保护。(The invention provides an A-type foot-and-mouth disease virus-like particle antigen which is assembled by antigen proteins of an A-type foot-and-mouth disease virus epidemic strain VP2, VP3 and VP1, wherein the antigen proteins of VP2, VP3 and VP1 are respectively encoded by nucleotide sequences of specific sequences. The vaccine prepared by the A type foot-and-mouth disease virus-like particle antigen has good immunogenicity aiming at the A type foot-and-mouth disease virus epidemic strain. The vaccine prepared by the antigen and the O type foot-and-mouth disease virus-like particle antigen can respectively protect against the A type foot-and-mouth disease virus epidemic strain and the O type foot-and-mouth disease virus.)

The A-type foot-and-mouth disease virus-like particle antigen is formed by assembling A-type foot-and-mouth disease virus epidemic strains VP2, VP3 and VP1 antigen proteins, the A-type foot-and-mouth disease virus VP2 antigen protein is coded by a nucleotide sequence shown by Seq ID No.1 or a degenerate sequence thereof, the A-type foot-and-mouth disease virus VP3 antigen protein is coded by a nucleotide sequence shown by Seq ID No.2 or a degenerate sequence thereof, and the A-type foot-and-mouth disease virus VP1 antigen protein is coded by a nucleotide sequence shown by Seq ID No.3 or a degenerate sequence thereof.

2. A vaccine composition comprising an immunizing amount of the type a foot-and-mouth disease virus-like particle antigen of claim 1 and a pharmaceutically acceptable carrier.

3. The vaccine composition according to claim 2, wherein the type A foot-and-mouth disease virus-like particle antigen content is 160-240 μ g/ml; preferably, the antigen content of the type A foot-and-mouth disease virus-like particle is 160 mug/ml, or 200 mug/ml, or 240 mug/ml.

4. The vaccine composition of claim 2, wherein the pharmaceutically acceptable carrier comprises an adjuvant selected from the group consisting of: (1) mineral oil, alumina gel adjuvant, saponin, alfvudine, DDA; (2) water-in-oil emulsion, oil-in-water emulsion, water-in-oil-in-water emulsion; or (3) a copolymer of a polymer of acrylic acid or methacrylic acid, maleic anhydride and an alkenyl derivative; and one or more of RIBI adjuvant system, Block co-polymer, SAF-M, monophosphoryl lipid A, Avridine lipid-amine adjuvant, Escherichia coli heat-labile enterotoxin, cholera toxin, IMS 1314, muramyl dipeptide, Montanide ISA 206, and Gel adjuvant; preferably, the saponin is Quil A, QS-21, GPI-0100; preferably, the adjuvant is ISA 206 adjuvant.

The adjuvant content is 5% -60% V/V, preferably from 30% -60% V/V, more preferably 50% V/V.

5. The vaccine composition according to claim 2, wherein the vaccine composition further comprises an immunizing amount of type O foot-and-mouth disease SEA topology like particle antigen and/or an immunizing amount of type O foot-and-mouth disease CATHAY topology like particle antigen; wherein the content of the first and second substances,

the O-type foot-and-mouth disease SEA topological virus-like particle antigen is assembled by O-type foot-and-mouth disease SEA topological virus epidemic strains VP4, VP2, VP3 and VP1 antigen proteins, wherein the O-type foot-and-mouth disease SEA topological virus VP4 antigen protein is a nucleotide sequence shown in Seq ID No.4 or a degenerate sequence code thereof, the O-type foot-and-mouth disease SEA topological virus VP2 antigen protein is a nucleotide sequence shown in Seq ID No.5 or a degenerate sequence code thereof, the O-type foot-and-mouth disease SEA topological virus VP3 antigen protein is a nucleotide sequence shown in Seq ID No.6 or a degenerate sequence code thereof, and the O-type foot-and-mouth disease SEA topological virus VP1 antigen protein is a nucleotide sequence shown in Seq ID No.7 or a degenerate sequence code thereof; and

the O-type foot-and-mouth disease CATHOY topological virus-like particle antigen is assembled by O-type foot-and-mouth disease CATHOY topological virus epidemic strains VP0, VP3 and VP1 antigen proteins, wherein the O-type foot-and-mouth disease CATHOY topological virus VP0 antigen protein is a nucleotide sequence shown in Seq ID No.8 or a degenerate sequence code thereof, the O-type foot-and-mouth disease CATHOY topological virus VP3 antigen protein is a nucleotide sequence shown in Seq ID No.9 or a degenerate sequence code thereof, and the O-type foot-and-mouth disease CATHOY topological virus VP1 antigen protein is a nucleotide sequence shown in Seq ID No.10 or a degenerate sequence code thereof.

6. The vaccine composition according to claim 5, wherein the antigen content of the foot-and-mouth disease type O SEA topological type virus-like particles is 100-200 μ g/ml; preferably, the antigen content of the SEA topological type foot-and-mouth disease virus-like particle is 100 mug/ml, 150 mug/ml or 200 mug/ml;

the content of the O-type foot-and-mouth disease CATHOY topological virus-like particle antigen is 100-200 mug/ml; preferably, the antigen content of the type O foot-and-mouth disease CATHOY topological type virus-like particles is 100 mug/ml, or 150 mug/ml, or 200 mug/ml.

7. A method of preparing the vaccine composition of claim 2, wherein the method comprises:

respectively cloning and recombining a gene of the A-type foot-and-mouth disease virus VP2 antigen protein, a gene of the A-type foot-and-mouth disease virus VP3 antigen protein and a gene of the A-type foot-and-mouth disease virus VP1 antigen protein to a same tandem expression vector;

transforming or transducing the recombinant expression vector of the step (1) to a host, wherein the recombinant SUMO-VP2 antigen protein, the recombinant SUMO-VP3 antigen protein and the recombinant SUMO-VP1 antigen protein of the A-type foot-and-mouth disease virus are subjected to soluble expression, and the expressed recombinant SUMO-VP2 antigen protein, the recombinant SUMO-VP3 antigen protein and the recombinant SUMO-VP1 antigen protein of the A-type foot-and-mouth disease virus can be self-assembled into virus-like particle antigen;

separating and purifying the recombinant antigen of the A-type foot-and-mouth disease virus in the step (2), and performing enzyme digestion and purification to remove the SUMO fusion tag; and

and (4) self-assembling the virus-like particle antigen, and adding an adjuvant to obtain the vaccine composition.

8. The method according to claim 7, wherein the tandem expression vector of step (1) is pET28a, pET28b, pET32 a; the host of the step (2) is E.coli BL21(DE3), Origami B (DE3) pLysS, Rosetta-gami B (DE 3).

9. The method according to claim 7, wherein the protein expression is induced in step (2) by adding IPTG after the host cell is expanded.

10. Use of the vaccine composition according to claims 2-6 for the preparation of a medicament for the prevention and/or treatment of type a foot and mouth disease.

Technical Field

The present invention belongs to a viral antigen and a medical preparation of the antigen. Specifically, the invention relates to a foot-and-mouth disease virus-like particle antigen, a vaccine composition prepared from the same, and a preparation method and application of the vaccine composition.

Background

Foot-and-mouth disease (FMD), an acute, highly contagious and rapidly remotely transmissible disease of animals, is the most contagious disease in mammals, with cloven-hoof infections causing significant economic losses worldwide. Animals suffering from foot and mouth disease include cattle, sheep and pigs. The pathogenic factor is foot-and-mouth disease virus (FMDV), which is a aphtha virus of picornavirus family. The virus is divided into 7 serotypes (A, O, C, Asia1, SAT1, SAT2 and SAT 3), wherein the type-O foot-and-mouth disease virus and the type-A foot-and-mouth disease virus are mainly prevalent in China. Vaccine immunization is an effective measure for controlling the disease and protecting livestock from harm.

With the continuous spread of the A-type foot-and-mouth disease, the A-type foot-and-mouth disease virus popular in China is greatly changed, and is different from the traditional method in that the A-type foot-and-mouth disease virus mainly causes infection and morbidity of cattle and sheep in the natural epidemic process, and the number of cases of pigs is small; however, the type A foot-and-mouth disease which is epidemic at present is pathogenic to cattle and pigs, and the toxicity of the type A foot-and-mouth disease is 10 times higher than that of the type A virus. The market lacks a vaccine with both superior biological safety and immune effect.

Virus-like particles (VLPs) are viroid particles that are capable of self-packaging into a viral coat structure upon expression in vitro and/or in vivo, and are pseudoviruses that have a similar coat structure to a virus but do not have the ability to replicate a virus. The VLPs vaccine can effectively stimulate the organism to generate anti-infection and anti-tumor immunity, and the vaccine designed based on the virus-like particles is an ideal vaccine form. Therefore, screening an ideal foot-and-mouth disease strain sequence to prepare the virus-like particles is urgent, and meets the requirements of effective prevention and control of major animal epidemic diseases and guarantee of healthy and sustainable development of animal husbandry proposed by China.

Disclosure of Invention

In order to solve the problem of A type foot-and-mouth disease virus epidemic strains in the prior art, the invention provides an A type foot-and-mouth disease virus-like particle antigen, wherein the A type foot-and-mouth disease virus-like particle antigen is assembled by A type foot-and-mouth disease virus epidemic strains VP2, VP3 and VP1 antigen proteins, the A type foot-and-mouth disease virus VP2 antigen protein is a nucleotide sequence shown in Seq ID No.1 or a degenerate sequence code thereof, the A type foot-and-mouth disease virus VP3 antigen protein is a nucleotide sequence shown in Seq ID No.2 or a degenerate sequence code thereof, and the A type foot-and-mouth disease virus VP1 antigen protein is a nucleotide sequence shown in Seq ID No.3 or a degenerate sequence code thereof.

The foot-and-mouth disease virus-like particle antigen has good immunogenicity, and the vaccine composition prepared by the antigen can provide complete protection for the A-type foot-and-mouth disease virus epidemic strain by only one-time immunization. Meanwhile, the foot-and-mouth disease virus-like particle antigen has good stability, is placed at 4 ℃ for 3 months, and is still full and free of aggregation through phosphotungstic acid negative staining and electron microscope observation.

The A-type foot-and-mouth disease virus-like particle antigen is derived from the current epidemic strain and can generate complete protection against the current epidemic wild strain.

The invention also provides a vaccine composition, wherein the vaccine composition comprises an immunizing amount of the A-type foot-and-mouth disease virus-like particle antigen and a pharmaceutically acceptable carrier.

When the antigen content of the A-type epidemic foot-and-mouth disease virus-like particle vaccine is only 160 mu g/ml, the 14 th day after immunization can also reach the antibody titer of more than 1:128, and the A-type epidemic foot-and-mouth disease virus-like particle vaccine can maintain the high-titer antibody titer for a long period and can generate protection against the whole fattening period; showing good immunogenicity.

In one embodiment of the present invention, the vaccine composition of the present invention contains 160 to 240 μ g/ml of antigen of the type a foot-and-mouth disease virus-like particle.

The antigen content of the A-type epidemic foot-and-mouth disease virus-like particles can be selected from 160 mu g/ml, 170 mu g/ml, 180 mu g/ml, 190 mu g/ml, 200 mu g/ml, 210 mu g/ml, 220 mu g/ml, 230 mu g/ml and 240 mu g/ml.

Even when the antigen content of the A-type epidemic foot-and-mouth disease virus-like particle is only 160 mu g/ml, the 14 th day after immunization can achieve the antibody titer of more than 1:128, namely, the immunoprotection can be generated, and the antibody titer with high titer can be maintained for a long period of time.

In a preferred embodiment of the present invention, the vaccine composition of the present invention comprises 160 μ g/ml, or 200 μ g/ml, or 240 μ g/ml of antigen of the type a foot-and-mouth disease virus-like particle.

As an embodiment of the present invention, in the vaccine composition of the present invention, the pharmaceutically acceptable carrier includes an adjuvant selected from the group consisting of: (1) mineral oil, alumina gel adjuvant, saponin, alfvudine, DDA; (2) water-in-oil emulsion, oil-in-water emulsion, water-in-oil-in-water emulsion; or (3) a copolymer of a polymer of acrylic acid or methacrylic acid, maleic anhydride and an alkenyl derivative; and one or more of RIBI adjuvant system, Block co-polymer, SAF-M, monophosphoryl lipid A, Avridine lipid-amine adjuvant, Escherichia coli heat-labile enterotoxin, cholera toxin, IMS 1314, muramyl dipeptide, Montanide ISA 206, and Gel adjuvant; preferably, the saponin is Quil A, QS-21, GPI-0100; preferably, the adjuvant is ISA 206 adjuvant.

The adjuvant content is 5% -60% V/V, preferably from 30% -60% V/V, more preferably 50% V/V.

In one embodiment of the present invention, the vaccine composition further comprises an immunizing amount of type O foot-and-mouth disease SEA topological type virus-like particle antigen and/or an immunizing amount of type O foot-and-mouth disease CATHAY topological type virus-like particle antigen; the O-type foot-and-mouth disease SEA topological virus-like particle antigen is assembled by O-type foot-and-mouth disease SEA topological virus epidemic strains VP4, VP2, VP3 and VP1 antigen proteins, wherein the O-type foot-and-mouth disease SEA topological virus VP4 antigen protein is encoded by a nucleotide sequence shown by Seq ID No.4 or a degenerate sequence thereof, the O-type foot-and-mouth disease SEA topological virus VP2 antigen protein is encoded by a nucleotide sequence shown by Seq ID No.5 or a degenerate sequence thereof, the O-type foot-and-mouth disease SEA topological virus VP3 antigen protein is encoded by a nucleotide sequence shown by Seq ID No.6 or a degenerate sequence thereof, and the O-type foot-and-mouth disease SEA topological virus VP1 antigen protein is encoded by a nucleotide sequence shown by Seq ID No.7 or a degenerate sequence thereof; and the O-type foot-and-mouth disease CATHOY topological virus-like particle antigen is assembled by O-type foot-and-mouth disease CATHOY topological virus epidemic strains VP0, VP3 and VP1 antigen proteins, wherein the O-type foot-and-mouth disease CATHOY topological virus VP0 antigen protein is coded by a nucleotide sequence shown by Seq ID No.8 or a degenerate sequence thereof, the O-type foot-and-mouth disease CATHOY topological virus VP3 antigen protein is coded by a nucleotide sequence shown by Seq ID No.9 or a degenerate sequence thereof, and the O-type foot-and-mouth disease CATHOY topological virus VP1 antigen protein is coded by a nucleotide sequence shown by Seq ID No.10 or a degenerate sequence thereof.

The O-type foot-and-mouth disease SEA topological virus-like particle antigen has good immunogenicity, and the O-type foot-and-mouth disease SEA topological antibody titer of more than 1:128 can be achieved 14 days after vaccine immunization. The O-type foot-and-mouth disease SEA topological virus-like particle antigen has good stability, is placed at 4 ℃ for 3 months, and is subjected to phosphotungstic acid negative staining and electron microscope observation, so that the virus-like particles are still plump and have no aggregation phenomenon.

The O-type foot-and-mouth disease CATHOY topological virus-like particle antigen has good immunogenicity, and the O-type foot-and-mouth disease CATHOY topological antibody titer of more than 1:128 can be achieved 14 days after vaccine immunization. The O-type foot-and-mouth disease CATHOY topological virus-like particle antigen has good stability, is placed at 4 ℃ for 3 months, and is subjected to phosphotungstic acid negative staining and electron microscope observation to show that virus-like particles are still plump without aggregation.

In a preferred embodiment of the invention, the vaccine composition of the invention comprises an antigen content of the SEA topologic type foot-and-mouth disease virus-like particles of type O in an amount of 100-200 μ g/ml; the content of the O-type foot-and-mouth disease CATHOY topological virus-like particle antigen is 100-200 mug/ml.

The antigen content of the SEA topological type virus-like particle of the foot-and-mouth disease type O can be selected from 100 mu g/ml, 110 mu g/ml, 120 mu g/ml, 130 mu g/ml, 140 mu g/ml, 150 mu g/ml, 160 mu g/ml, 170 mu g/ml, 180 mu g/ml, 190 mu g/ml and 200 mu g/ml.

Even when the antigen content of the type-O foot-and-mouth disease SEA topological virus-like particles is only 100 mu g/ml, the antibody titer of more than 1:128 can be achieved on the 14 th day after immunization, thus the immunoprotection can be generated, the high-titer antibody titer can be maintained for a long time, and the excellent immunogenicity is shown.

The antigen content of the O-type foot-and-mouth disease CATHOY topological type virus-like particle can be selected from 100 mu g/ml, 110 mu g/ml, 120 mu g/ml, 130 mu g/ml, 140 mu g/ml, 150 mu g/ml, 160 mu g/ml, 170 mu g/ml, 180 mu g/ml, 190 mu g/ml and 200 mu g/ml.

Even when the content of the O-type foot-and-mouth disease CATHOY topological type virus-like particle antigen is only 100 mu g/ml, the 14 th day after immunization can reach the antibody titer of more than 1:128, thus generating immune protection, maintaining the high-titer antibody titer for a long time and showing good immunogenicity.

The vaccine composition contains the A type foot-and-mouth disease virus-like particle antigen, the O type foot-and-mouth disease SEA topological type virus-like particle antigen and the O type foot-and-mouth disease CATHOY topological type virus-like particle antigen, the two O type foot-and-mouth disease virus-like particle antigens are synergistic, and the immune effect of each component of a single vaccine can be exerted even if the antigen content is reduced by half.

As a more preferable embodiment of the invention, in the vaccine composition of the invention, the antigen content of the SEA topologic type foot-and-mouth disease virus-like particles is 100 μ g/ml, or 150 μ g/ml, or 200 μ g/ml; and the content of the O-type CATHAY topological type foot-and-mouth disease virus-like particle antigen is 100 mu g/ml, or 150 mu g/ml, or 200 mu g/ml.

As one embodiment of the present invention, the pharmaceutically acceptable carrier includes drugs, immunostimulants, antioxidants, surfactants, colorants, volatile oils, buffers, dispersants, propellants, and preservatives; the immunostimulant includes alpha-interferon, beta-interferon, gamma-interferon, granulocyte macrophage colony stimulating factor (GM-CSF), macrophage colony stimulating factor (M-CSF), and interleukin 2(IL 2).

To prepare such compositions, methods well known in the art may be used.

The invention also relates to a method for preparing the vaccine composition, wherein the method comprises the following steps: respectively cloning and recombining a gene of the A-type foot-and-mouth disease virus VP2 antigen protein, a gene of the A-type foot-and-mouth disease virus VP3 antigen protein and a gene of the A-type foot-and-mouth disease virus VP1 antigen protein to a same tandem expression vector; transforming or transducing the recombinant expression vector of the step (1) to a host, wherein the recombinant SUMO-VP2 antigen protein, the recombinant SUMO-VP3 antigen protein and the recombinant SUMO-VP1 antigen protein of the A-type foot-and-mouth disease virus are subjected to soluble expression, and the expressed recombinant SUMO-VP2 antigen protein, the recombinant SUMO-VP3 antigen protein and the recombinant SUMO-VP1 antigen protein of the A-type foot-and-mouth disease virus can be self-assembled into virus-like particle antigen; separating and purifying the recombinant antigen of the A-type foot-and-mouth disease virus in the step (2), and performing enzyme digestion and purification to remove the SUMO fusion tag; and (4) self-assembling the virus-like particle antigen, and adding an adjuvant to obtain the vaccine composition. The invention can obtain stable self-assembled virus-like particles by expressing antigen proteins of A-type epidemic strains of foot-and-mouth disease viruses VP2, VP3 and VP 1; through tandem expression of antigen proteins of A-type epidemic foot-and-mouth disease viruses VP2, VP3 and VP1, subsequent antigen purification and separation are facilitated. The expressed and purified active protein can be efficiently self-assembled into the A-type epidemic strain foot-and-mouth disease virus-like particle antigen.

As an embodiment of the invention, in the method of the invention, the tandem expression vector of the step (1) is pET28a, pET28b, pET32 a; the host of the step (2) is E.coli BL21(DE3), Origami B (DE3) pLysS, Rosetta-gami B (DE 3).

According to the invention, tandem expression is carried out on VP2, VP3 and VP1 antigen proteins by selecting a tandem expression vector and host bacteria, so that subsequent antigen separation and purification are facilitated, and the procedure is simplified. The soluble proteins expressed, purified and self-assembled into virus-like particles are biologically active.

As a preferred embodiment of the present invention, in the method of the present invention, IPTG is added after the host cells are amplified in the step (2), and the protein expression is induced.

In a preferred embodiment of the present invention, in the separation and purification step of step (3), the virus-like particle antigen is purified by ammonium sulfate fractionation and chromatography by taking the supernatant after disruption of the bacterial cells.

The invention adopts three structural proteins VP2, VP3 and VP1 of the A-type foot-and-mouth disease virus for the first time to produce the foot-and-mouth disease virus-like particles, and has the advantages of good immunogenicity, no biological safety risk and the like. The virus-like particle vaccine composition prepared by the invention can provide protective activity for A-type epidemic strain foot-and-mouth disease, and has the advantages of fast antibody generation, high antibody generation level, long immune duration and capability of maintaining long-time immune protection.

The invention also relates to application of the vaccine composition in preparing a medicament for preventing and/or treating the type A foot-and-mouth disease.

The subject of the invention for preparing the medicament for preventing and/or treating foot-and-mouth disease virus infection comprises pigs.

After one-time immunization, the vaccine composition can maintain the antibody titer of more than 1:128 in 133 days, and can completely protect the pig body, and the time can cover the whole fattening period.

Detailed Description

Hereinafter, embodiments of the present invention will be described.

Definition of

The foot-and-mouth disease virus belongs to the small RNA virus family, the aphtha virus genus, the virus has O, A, C, SAT1, SAT2, SAT3 (namely south Africa foot-and-mouth disease virus types 1, 2 and 3) and Asia1 (Asia type 1) 7 serotypes, cross protection reaction does not exist among the types, and each type has a plurality of subtypes. A positive-stranded RNA, which is single-stranded in the center of the virus, consists of about 8000 bases and is the basis for infection and inheritance; the surrounding protein determines the antigenicity, immunity and serological reaction capability of the virus; the viral coat is a symmetrical 20-sided body. Foot-and-mouth disease virus is a highly infectious disease of even-hoof animals, namely, the pathogeny of foot-and-mouth disease, the foot-and-mouth disease is listed as the first infectious disease list of A animals by the International animal epidemic department, the foot-and-mouth disease is listed as the infectious disease list of entry animals by China, the foot-and-mouth disease is prevented and treated in China, the prevention is mainly inoculated through vaccine injection, and the animals with the foot-and-mouth disease are killed.

"Antigen" refers to a substance that induces an immune response in the body, i.e., a substance that is specifically recognized and bound by an Antigen receptor (TCR/BCR) on the surface of T/B lymphocytes, activates T/B cells, proliferates and differentiates the T/B cells, produces an immune response product (sensitized lymphocytes or antibodies), and specifically binds to the corresponding product in vitro or in vivo.

"Virus-like particles (VLPs)" are particles assembled from one or more viral structural proteins and have similar external structure and antigenicity to viral particles, but do not contain viral genes.

"foot-and-mouth disease virus VP2, VP3, VP1 antigen protein": FMDV structural protein precursor protein P1 is processed catalytically by protease 3C into VP0, VP3 and VP1, which 3 proteins are capable of self-assembly into an icosahedral viral capsid. The VP0 protein is an intermediate after cleavage of P1 by protease 3C, and VP0 is cleaved mature into VP4 and VP2 at the final stage of virion formation.

The terms "vaccine", "vaccine composition" as used herein refer to a pharmaceutical composition comprising a foot and mouth disease virus-like particle antigen which induces, stimulates or enhances an immune response in pigs against foot and mouth disease only.

The term "immunizing amount" shall be understood as an "immunologically effective amount," also referred to as an immunoprotective amount or an amount effective to produce an immune response, of antigen effective to induce an immune response in a recipient, sufficient to prevent or ameliorate the signs or symptoms of disease, including adverse health effects or complications thereof. The immune response may be sufficient for diagnostic purposes or other testing, or may be suitable for use in preventing signs or symptoms of disease, including adverse health consequences or complications thereof caused by infection by a pathogen. Humoral immunity or cell-mediated immunity or both can be induced. The immune response of an animal to an immunogenic composition can be assessed indirectly, for example, by measuring antibody titers, lymphocyte proliferation assays, or directly by monitoring signs or symptoms after challenge with a wild-type strain, while the protective immunity provided by the vaccine can be assessed by measuring, for example, clinical signs such as mortality, reduction in morbidity, temperature values, overall physiological condition of the subject, and overall health and performance. The immune response may include, but is not limited to, induction of cellular and/or humoral immunity.

The term "pharmaceutically acceptable carrier" refers to all other ingredients in the vaccine composition of the present invention, except for the foot-and-mouth disease virus antigen, which do not stimulate the body and do not hinder the biological activity and properties of the compound used, or a diluent, preferably an adjuvant. The term "adjuvant" may include an alumina gel adjuvant; saponins (saponin), such as Quil A, QS-21(Cambridge Biotech Incorporation, Cambridge MA), GPI-0100(Galenica Pharmaceuticals Incorporation, Birmingham AL); a water-in-oil emulsion; an oil-in-water emulsion; a water-in-oil-in-water emulsion; polymers of acrylic acid or methacrylic acid; maleic anhydride and alkenyl (alkenyl) derivatives. The term "emulsion" may be based in particular on light liquid paraffin oil (European Pharmacopea type); isoprenoid oils (isoprenoid oils) resulting from the oligomerization of olefins, such as squalane (squalane) or squalene oil (squalene oil), in particular isobutene or decene; linear alkyl-containing esters of acids or alcohols, more particularly vegetable oils, ethyl oleate, propylene glycol di- (caprylate/caprate), glycerol tri- (caprylate/caprate) or propylene glycol dioleate; esters of branched fatty acids or alcohols, especially isostearic acid esters. The oil is used in combination with an emulsifier to form an emulsion. The emulsifiers are preferably nonionic surfactants, in particular esters of sorbitan, of mannide (such as, for example, anhydrous mannitol oleate), of aliphatic diols (glycols), of polyglycerols, of propylene glycol and of oleic acid, of isostearic acid, of ricinoleic acid or of hydroxystearic acid, which are optionally ethoxylated, and also polyoxypropylene-polyoxyethylene block copolymers, in particular the Pluronic products, in particular L121. See The description of The same and The reactive application of adjuvants by Hunter et al (Ed. by DES Stewart-Tull, John Wiley and Sons, New York,1995:51-94) and The description of Vaccine by Todd et al (1997,15: 564-570). For example, the SPT emulsion described on page 147 and the MF59 emulsion described on page 183 of Vaccine design, the Subunit and adivant propaach (Plenum Press,1995) written by Powell M and Newman M can be used. The term "polymer of acrylic or methacrylic acid" is preferably a crosslinked polymer of acrylic or methacrylic acid, in particular a polyalkenyl ether or polyalcohol crosslinked with a sugar (sugar), these compounds being known under the name Carbomer (Carbopol, trade name Carbopol) (Phameuropa,1996,8 (2)). Those skilled in the art can also see US2909462, which describes such acrylic polymers crosslinked with polyhydroxylated compounds having at least 3 hydroxyl groups, preferably not more than 8, wherein the hydrogen atoms of at least 3 hydroxyl groups are substituted by unsaturated aliphatic hydrocarbon groups (aliphatic radial) having at least 2 carbon atoms. Preferred groups are those containing 2 to 4 carbon atoms, such as vinyl, allyl and other ethylenically unsaturated groups (ethylenically unsaturated groups). The unsaturated groups may themselves contain other substituents, such as methyl. These products are sold under the name carbopol, (BF Goodrich, Ohio, USA) are particularly suitable. They are crosslinked with allyl sucrose or with allyl pentaerythritol. Among these, mention may be made of carbopols 974P, 934P and 971P, the most preferred being the use of carbopol 971P. The term "copolymers of maleic anhydride and alkenyl derivative" also contemplates the maleic anhydride and ethylene copolymers ema (monsanto), which are dissolved in water to give an acidic solution, neutralized, preferably to physiological pH, in order to give an adjuvant solution into which the immunogenic, immunogenic or vaccinal composition itself can be incorporated. The term "adjuvant" also includes, but is not limited to, the RIBI adjuvant system (Ribi Incorporation), Block co-polymer (CytRx, Atlanta GA), SAF-M (Chiron, Emeryville CA), monophosphoryl lipid A (monophosphoryl lipid A), Avridine lipoamine adjuvant, E.coli heat labile enterotoxin (recombinant or otherwise), cholera toxin, IMS 1314, muramyl dipeptide, Gel adjuvant, and the like. Preferably, the adjuvant comprises one or more of white oil, an alumina Gel adjuvant, a saponin, a water-in-oil emulsion, an oil-in-water emulsion, a water-in-oil-in-water emulsion, a polymer of acrylic acid or methacrylic acid, a copolymer of maleic anhydride and an alkenyl (alkenyl) derivative, a RIBI adjuvant system, a Block co-polymer, SAF-M, a monophosphoryl lipid A, Avridine lipid-amine adjuvant, escherichia coli heat labile enterotoxin, cholera toxin, IMS 1314, muramyl dipeptide, Montanide ISA 206 or Gel adjuvant.

"degenerate sequence": in molecular biology, the phenomenon that the same amino acid has two or more codons is called degeneracy of the codon (degeneracy), and such a sequence is called degenerate sequence.

"Gene recombination": refers to the recombination of genes that control different traits. Modern genetic engineering techniques carry out genetic recombination, also called recombinant DNA, in vitro by artificial design, with the aim of transferring a genetic gene in one individual cell to another individual cell DNA molecule of a different character, causing genetic variation. After the target gene from the donor is transferred into the recipient bacterium, the expression of the gene product can be carried out, thereby obtaining a product which is difficult to obtain by a common method.

"transformation" refers to the acquisition of a new genetic phenotype in a cell or a cultured recipient cell by the automated acquisition or artificial supply of exogenous DNA.

"transduction" means that when the virus is released from an infected (donor) cell and re-infects another (recipient) cell, the DNA transfer and gene recombination that occurs between the donor and recipient cells is transduction.

The term "preventing and/or treating" when referring to foot and mouth disease virus infection means inhibiting replication of foot and mouth disease virus, inhibiting spread of foot and mouth disease virus or preventing colonization of foot and mouth disease virus in its host, and alleviating symptoms of foot and mouth disease virus infected diseases or conditions. Treatment is considered to be therapeutically effective if the viral load is reduced, the condition is reduced and/or the food intake and/or growth is increased.

The invention will be further described with reference to specific embodiments, and the advantages and features of the invention will become apparent as the description proceeds. These examples are illustrative only and do not limit the scope of the present invention in any way. It will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention, and that such changes and modifications may be made without departing from the spirit and scope of the invention.

The chemical reagents used in the examples of the present invention are all analytical reagents and purchased from the national pharmaceutical group. The experimental methods are conventional methods unless specified otherwise; the biomaterial is commercially available unless otherwise specified.

Examples

Materials and methods

Construction and transformation of vectors

Recombinant vector pET28a-SUMOVP2-SUMOVP3-SUMOVP1 containing type A foot-and-mouth disease virus VP2, VP3 and VP1 genes

A type-A foot-and-mouth disease virus VP2 gene fragment shown in a sequence table SEQ ID NO.1, a type-A foot-and-mouth disease virus VP3 gene fragment shown in a sequence table SEQ ID NO.2 and a type-A foot-and-mouth disease virus VP1 gene fragment shown in a sequence table SEQ ID NO.3 are synthesized by Suzhou Jinzhi Biotech Co., Ltd and are respectively connected with a pETSUMO vector. Then, fragments containing RBS-SUMO-VP2, T7-RBS-SUMO-VP3 and T7-RBS-SUMO-VP1 were amplified using the successfully ligated recombinant plasmids as templates, respectively. The fragments obtained by digestion with Xba I/BamH I, Sac I/Sal I and Not I/Xho I, respectively, were sequentially cloned into pET28a vector.

Ligation products were transformed with CaCl₂The prepared DH5 alpha competent cells were plated on a kanamycin-resistant solid LB medium, and when colonies of the monoclonals were clearly visible, the monoclonals were picked up in a LB liquid medium containing kanamycin, cultured at 37 ℃ at 230 rpm for 12 hours overnight, and the recombinant plasmid pET28a-SUMOVP2-SUMOVP3-SUMOVP1 was extracted.

The recombinant plasmid pET28a-SUMOVP2-SUMOVP3-SUMOVP1 inserted with the gene of type A foot-and-mouth disease virus VP2, VP3, VP1 was transformed into 40. mu.l of competent Escherichia coli BL21(DE3) prepared by calcium chloride method, spread on kanamycin-resistant solid LB medium, cultured at 37 ℃ for 10-12 hours until the single colony becomes clearly visible, picked up into a test tube containing 4ml of kanamycin-resistant liquid LB medium, cultured at 37 ℃ for 12 hours with shaking at 230 rpm, and 1ml of the culture solution was freeze-dried at-80 ℃ for storage.

Recombinant vector containing type O foot-and-mouth disease SEA topological virus VP4, VP2, VP3 and VP1 genes

An O-type SEA topological VP4 gene fragment shown in a sequence table SEQ ID NO.4, an O-type SEA topological VP2 gene fragment shown in a sequence table SEQ ID NO.5, an O-type SEA topological VP3 gene fragment shown in a sequence table SEQ ID NO.6 and an O-type SEA topological VP1 gene fragment shown in a sequence table SEQ ID NO.7 are synthesized by Suzhou Jinzhi biotechnology, Inc., and Escherichia coli expression strains with recombinant plasmids pET28a-SUMOVP4-SUMOVP2-SUMOVP 3-MOVP 1 and genes capable of expressing O-type foot-and-mouth disease SEA topological viruses VP4, VP2, VP3 and VP1 in series are constructed and are freeze-dried and stored at-80 ℃.

Recombinant vector containing O type foot-and-mouth disease CATHAY topological virus VP0, VP3 and VP1 genes

An O-type CATHOY topological VP0 gene fragment shown in a sequence table SEQ ID NO.8, an O-type CATHOY topological VP3 gene fragment shown in a sequence table SEQ ID NO.9 and an O-type CATHOY topological VP1 gene fragment shown in a sequence table SEQ ID NO.10 are synthesized by Suzhou Jinzhi biotechnology Limited to construct an escherichia coli expression strain with recombinant plasmids pET28a-SUMOVP0-SUMOVP3-SUMOVP1 and genes capable of expressing O-type foot-and-mouth disease CATHOY topological viruses VP0, VP3 and VP1 in series, and the escherichia coli expression strain is freeze-dried and stored at the temperature of-80 ℃.

Expression, purification and assembly of antigen protein and identification of foot-and-mouth disease virus-like particle

Type A foot-and-mouth disease virus antigen and virus-like particle

Coli strain harboring the recombinant plasmid pET28a-SUMOVP2-SUMOVP3-SUMOVP1 was taken out from-80 ℃ and inoculated with 50ml of LB liquid medium resistant to kanamycin, and after shaking culture at 37 ℃ and 230 rpm for 12 hours, it was transferred to 1L of LB liquid medium and cultured at 37 ℃ to prepare a seed liquid for fermentation.

The fermentation tank was a 50L fermentation tank of Shanghai Baoxing Bio Inc., 30L of the medium was prepared and charged into the fermentation tank, and sterilized at 121 ℃ for 30 minutes. The next day, 3L of the seed solution was inoculated into a fermenter, and when the concentration of the culture solution reached about 10 OD600, the culture temperature was lowered to 25 ℃ and IPTG was added to a final concentration of 0.5mM for induction culture for 12 hours. The culture was stopped at a fermentation density of about 40 (OD600), and the cells were collected by centrifugation.

Resuspend the cells and crush the cells 4 times with a homogenizer at 800bar pressure. 13500rpm, and centrifuged for 40min, and the supernatant was collected and examined by 15% SDS-PAGE. And (3) carrying out protein coarse purification by adopting an ammonium sulfate fractional precipitation method, and then carrying out chromatographic purification, enzyme digestion and chromatographic purification to remove the SUMO fusion tag and the assembly of the A-type foot-and-mouth disease virus-like particles. The purified protein was detected by SDS-PAGE electrophoresis.

The foot-and-mouth disease virus-like particle A is observed by phosphotungstic acid negative staining and an electron microscope.

O type foot-and-mouth disease SEA topological type virus-like particle antigen and virus-like particle

Coli strain harboring the recombinant plasmid pET28a-SUMOVP4-SUMOVP2-SUMOVP3-SUMOVP1 was taken out from-80 ℃ and inoculated with 50ml of LB liquid medium resistant to kanamycin, and the strain was cultured under conditions similar to those described above for the preparation of type A foot-and-mouth disease virus antigen, and then transferred to 1L of LB liquid medium and cultured at 37 ℃.

And (3) fermenting and expressing the O type foot-and-mouth disease SEA topological virus antigen in a 50L fermentation tank in a large scale according to the similar preparation conditions of the A type foot-and-mouth disease virus antigen.

And separating, purifying and identifying four O-type foot-and-mouth disease SEA topological virus antigens expressed in series in the thalli according to the similar preparation conditions of the A-type foot-and-mouth disease virus antigen.

And (3) observing the O-type foot-and-mouth disease SEA topological virus-like particles by phosphotungstic acid negative staining and an electron microscope.

O type foot-and-mouth disease CATHOY topological type virus-like particle antigen and virus-like particle

Coli strain harboring the recombinant plasmid pET28a-SUMOVP0-SUMOVP3-SUMOVP1 was taken out from-80 ℃ and inoculated with 50ml of LB liquid medium resistant to kanamycin, and the strain was cultured under conditions similar to those for the preparation of the type A foot-and-mouth disease virus antigen as described above, and then transferred to 1L of LB liquid medium and cultured at 37 ℃.

And (3) fermenting and expressing the O type foot-and-mouth disease CATHOY topological virus antigen in a 50L fermentation tank in a large scale according to the similar preparation conditions of the A type foot-and-mouth disease virus antigen.

Separating, purifying and identifying three O-type foot-and-mouth disease CATHOY topological virus antigens expressed in tandem in the thallus according to the similar preparation conditions of the A-type foot-and-mouth disease virus antigen.

And (3) observing the O-type foot-and-mouth disease CATHOY topological virus-like particles by phosphotungstic acid negative staining and an electron microscope.

Preparation of foot-and-mouth disease virus-like particle vaccine composition

Vaccine composition containing A type foot-and-mouth disease virus-like particle antigen

Slowly adding the prepared A-type foot-and-mouth disease virus-like particle antigen into an adjuvant, continuously stirring for 12min by using an emulsifying machine with the rotation speed of 800rpm in the adding process, uniformly mixing, and storing at 4 ℃ to obtain the vaccine composition containing the A-type foot-and-mouth disease virus-like particle antigen. Adjuvants suitable for use in the present invention may be those known to those skilled in the art. In the present invention, the adjuvant is selected to be a biphasic adjuvant (water-in-oil-in-water emulsion), for example, adjuvant ISA 206 (french seebeck).

Vaccine composition containing type A foot-and-mouth disease virus-like particle antigen and type O foot-and-mouth disease SEA topological type virus-like particle antigen

And (3) taking the prepared A-type foot-and-mouth disease virus-like particle antigen and O-type foot-and-mouth disease SEA topological type virus-like particle antigen, and preparing the vaccine composition according to the method for preparing the vaccine composition containing the A-type foot-and-mouth disease virus-like particle antigen. Adjuvants suitable for use in the present invention may be those known to those skilled in the art. In the present invention, the adjuvant is selected to be a biphasic adjuvant (water-in-oil-in-water emulsion), for example, adjuvant ISA 206 (french seebeck).

Vaccine composition containing A type foot-and-mouth disease virus-like particle antigen, O type foot-and-mouth disease SEA topological type virus-like particle antigen and O type foot-and-mouth disease CATHOY topological type virus-like particle antigen

And (3) taking the prepared A-type foot-and-mouth disease virus-like particle antigen, O-type foot-and-mouth disease SEA topological type virus-like particle antigen and O-type foot-and-mouth disease CATHOY topological type virus-like particle antigen, and preparing the vaccine composition according to the method for preparing the A-type foot-and-mouth disease virus-like particle antigen vaccine composition. Adjuvants suitable for use in the present invention may be those known to those skilled in the art. In the present invention, the adjuvant is selected to be a biphasic adjuvant (water-in-oil-in-water emulsion), for example, adjuvant ISA 206 (french seebeck).

Immunogenicity analysis of type A foot-and-mouth disease Virus-like particle vaccine compositions

Immunogenicity of type A foot-and-mouth disease virus-like particle vaccine compositions

And detecting the immunogenicity of the antigen in the vaccine composition by adopting the ELISA antibody level of the antibody in the immunized pig serum.

A healthy susceptible frame pig which is negative in both A-type foot-and-mouth disease virus antigen and antibody and has the weight of about 40kg is selected to immunize the prepared vaccine composition containing the A-type foot-and-mouth disease virus-like particle antigen, the immunization way is to inject 2ml of vaccine composition into neck muscles, and a blank control group is immunized with PBS with the same amount. Blood is collected from each pig before immunization of the vaccine, and blood is collected on 7 th day, 14 th day, 21 th day and 28 th day after immunization. And (3) detecting the antibody of the collected serum by using an A-type foot-and-mouth disease antibody ELISA detection kit.

Immunity duration experiment of A type foot-and-mouth disease virus-like particle vaccine composition

The duration of the immunization with the antigen in the vaccine composition was determined using the ELISA antibody levels of the antibodies in the sera of the immunized pigs.

Selecting healthy susceptible frame pigs with negative A-type foot-and-mouth disease virus antigens and negative antibodies and weight of about 40kg, immunizing to prepare a vaccine composition containing the A-type foot-and-mouth disease virus-like particle antigens, wherein the immunization route is to inject 2ml into neck muscles, immunizing an equal amount of PBS by a blank control group, immunizing uniformly, collecting blood for each pig before immunization of the vaccine, and collecting blood 21 days, 28 days, 35 days, 77 days, 105 days and 133 days after immunization.

A commercial inactivated vaccine (Re-O/MYA98/JSCZ/2013 strain + Re-A/WH/09 strain) immune group is used as a control group, the immune route is that 2ml is injected into neck muscles, a blank control group is used for immunizing PBS with the same amount, each pig is subjected to blood collection before vaccine immunization, blood collection is carried out on the 21 st day after immunization and the 2 nd immunization, and blood collection is carried out on the 7 th day, the 14 th day, the 56 th day, the 84 th day and the 112 th day after the 2 th immunization.

Antigen immunogenicity in vaccine composition containing type A foot-and-mouth disease virus-like particle antigen and type O foot-and-mouth disease SEA topological type virus-like particle antigen

And detecting the immunogenicity of the antigen in the vaccine composition by adopting the ELISA antibody level of the antibody in the immunized pig serum.

Selecting a healthy susceptible frame pig with negative A-type and O-type foot-and-mouth disease virus antigens and antibodies and a weight of about 40kg, immunizing the prepared vaccine composition containing the A-type foot-and-mouth disease virus-like particle antigen and the O-type foot-and-mouth disease SEA topological type virus-like particle antigen, wherein the immunization way is to inject 2ml of neck muscle, and the blank control group immunizes 2ml of PBS. Blood is collected from each pig before immunization of the vaccine, and blood is collected on 7 th day, 14 th day, 21 th day and 28 th day after immunization.

Antigen immunogenicity in vaccine composition containing type A foot-and-mouth disease virus-like particle antigen, type O foot-and-mouth disease SEA topological type virus-like particle antigen and type O foot-and-mouth disease CATHOY topological type virus-like particle antigen

And detecting the immunogenicity of the antigen in the vaccine composition by adopting the ELISA antibody level of the antibody in the immunized pig serum.

Selecting a healthy susceptible frame pig which is negative in both A-type and O-type foot-and-mouth disease virus antigens and antibodies and has the weight of about 40kg, immunizing the prepared vaccine composition containing the A-type foot-and-mouth disease virus-like particle antigen, the O-type foot-and-mouth disease SEA topological type virus-like particle antigen and the O-type foot-and-mouth disease CATHEY topological type virus-like particle antigen, wherein the immunization way is to inject 2ml into neck muscles, and the control group immunizes the vaccine composition containing the O-type foot-and-mouth disease SEA topological type virus-like particle antigen or the vaccine composition containing the O-type foot-and-mouth disease CATHEY topological type virus-like particle antigen, and the immunization way is to inject 2ml into neck muscles, and the blank control group immunizes PBS with the volume of 2 ml. Blood is collected from each pig before immunization of the vaccine, and blood is collected on 7 th day, 14 th day, 21 th day and 28 th day after immunization.

Example 1 type A foot-and-mouth disease Virus-like particles

And (3) resuspending the thallus expressing the A-type foot-and-mouth disease virus antigen protein, and detecting by SDS-PAGE electrophoresis to show that three target proteins expressed in tandem in the supernatant are expressed. SDS-PAGE electrophoresis detection shows that the purified protein is purified and enriched.

The phosphotungstic acid negative staining and electron microscope observation show that the A type foot-and-mouth disease protein forms virus-like particles, and the formed virus-like particles are full, high in assembly efficiency and free of aggregation. The foot-and-mouth disease virus-like particles are placed at 4 ℃ for 3 months, and then phosphotungstic acid negative staining and electron microscope observation show that the virus-like particles are still full and have no aggregation phenomenon. It is demonstrated that the foot-and-mouth disease protein prepared by the sequence screened by the invention forms stable virus-like particles.

Example 2 preparation of a type A foot-and-mouth disease Virus-like particle vaccine composition

The specific proportions of the components in the prepared vaccine are shown in table 1.

TABLE 1A foot-and-mouth disease Virus-like particle vaccine composition component ratio

Components	Vaccine 1	Vaccine 2	Vaccine 3
				Foot-and-mouth disease antigen (mu g/ml)	160	200	240
Biphasic adjuvant (V/V%)	50％	50％	50％

Example 3 immunogenicity testing of vaccine compositions containing type A foot-and-mouth disease Virus-like particle antigens

Selecting 20 healthy susceptible frame pigs with negative A-type foot-and-mouth disease virus antigen and antibody and weight of about 40kg, and randomly dividing the pigs into 4 groups with 5 heads in each group. Groups 1-3 are vaccine 1, vaccine 2, and vaccine 3 immunization groups prepared in example 2 of the present invention, respectively, and group 4 is a blank control group. The immunization group was administered by intramuscular injection of 2ml into the neck, and the control group was immunized with an equal amount of PBS.

The antibody titer result shows that the antibodies of all pigs are negative before the vaccine immunization, and the 14 th day after 1 immunization can reach more than 1: 128. The blank control group of pigs was negative for antibody and was unchanged. The specific results are shown in Table 2.

TABLE 2 type A foot-and-mouth disease ELISA antibody levels

The virus-like particles prepared by the invention can quickly form high-level specific antibodies, and even if the antigen content is only 160 mu g/ml, the virus-like particles can play a good immune protection role on the A-type foot-and-mouth disease on the 14 th day after immunization.

Example 4 immune duration comparison test of vaccine compositions containing type A foot and mouth disease Virus-like particle antigen

Selecting 20 healthy susceptible frame pigs with negative A-type foot-and-mouth disease virus antigen and antibody and weight of about 40kg, and randomly dividing the pigs into 4 groups with 5 heads in each group. The 5 th group is the vaccine 2 immunization group prepared in the embodiment 2 of the invention, the 7 th group is the commercial inactivated vaccine (Re-O/MYA98/JSCZ/2013 strain + Re-A/WH/09 strain) immunization group, and the 6 th group and the 8 th group are control groups. The immunization approach of the group 5 immunization group is to inject 2ml of PBS into neck muscle, the group 6 control group is immunized with PBS with the same amount, immunization is performed uniformly, each pig is subjected to blood collection before vaccine immunization, and the blood collection is performed 21 days, 28 days, 35 days, 77 days, 105 days and 133 days after immunization; the immunization route of the 7 th group immunization group is that 2ml is injected into neck muscle, the 8 th group control group is immunized with PBS with the same amount, each pig is subjected to blood collection before vaccine immunization, the 21 st day after the 7 th group and the 8 th group are immunized is subjected to blood collection and the 2 nd immunization is carried out, and the 7 th day, the 14 th day, the 56 th day, the 84 th day and the 112 th day after the 2 th immunization are respectively subjected to blood collection.

The results show that all the antibodies of the pigs before the vaccine immunization are negative, the vaccine 2 immunization group on the 21 st day after 1 immunization can reach more than 1:128, the commercial vaccine immunization group can not reach 1:128, and the commercial vaccine immunization group can reach 1:128 on the 7 th day after 2 immunizations; after the vaccine 2 immunization group immunizes for 1 time for 133 days, the high antibody level is still maintained, the ELISA antibody can reach 1:180 and above, and after the commercial vaccine immunization group immunizes for 2 times for 112 days, the antibody level of part of pigs approaches the 1:128 immunoprotection critical value. Control group pigs were negative for antibody and did not change. The specific results are shown in Table 3.

TABLE 3 comparison of type A foot-and-mouth disease ELISA antibody levels

The experiment shows that compared with the commercial whole virus inactivated vaccine, the virus-like particle vaccine composition prepared by the invention has the advantages that the antibody is generated quickly and has high antibody level, the A-type foot-and-mouth disease virus-like particle antigen can play a good immune protection role only through one-time immunization, the immune duration is obviously prolonged, and the immune protection can be maintained for a longer time.

Example 5 foot-and-mouth disease type O SEA topology-like particles

And (3) resuspending thalli expressing the protein antigen of the foot-and-mouth disease SEA topological virus of O type, and detecting by SDS-PAGE electrophoresis to show that four target proteins expressed in series in the supernatant are expressed. SDS-PAGE electrophoresis detection shows that the purified protein is purified and enriched.

The O-type foot-and-mouth disease SEA topological protein is seen to form virus-like particles through phosphotungstic acid negative staining and electron microscope observation, and the formed virus-like particles are full, high in assembly efficiency and free of aggregation. The foot-and-mouth disease virus-like particles are placed at 4 ℃ for 3 months, and then phosphotungstic acid negative staining and electron microscope observation show that the virus-like particles are still full and have no aggregation phenomenon. It is demonstrated that the foot-and-mouth disease protein prepared by the sequence screened by the invention forms stable virus-like particles.

EXAMPLE 6 preparation of SEA topology type O, bivalent foot-and-mouth disease Virus type A particle vaccine composition

The specific ratios of the components in the prepared vaccine are shown in table 4.

TABLE 4 ingredient ratio of SEA topology type O type and bivalent foot-and-mouth disease virus type A type bivalent particle vaccine composition

Components	Vaccine 4	Vaccine 5	Vaccine 6
				Type A foot-and-mouth disease antigen (mu g/ml)	160	200	240
Type O foot-and-mouth disease SEA topological antigen (mu g/ml)	100	150	200
				Biphasic adjuvant (V/V%)	50％	50％	50％

Example 7 immunogenicity testing of SEA topology type O, bivalent foot-and-mouth disease Virus type A particle vaccine compositions

Selecting 20 healthy susceptible frame pigs with negative A-type and O-type foot-and-mouth disease virus antigens and antibodies and weight of about 40kg, and randomly dividing the pigs into 4 groups with 5 heads in each group. Groups 9-11 are vaccine 4, vaccine 5, and vaccine 6 immunization groups prepared in example 6 of the present invention, respectively, and group 12 is a blank control group. The immunization route was 2ml intramuscular injection into the neck, and the control group was immunized with 2ml of PBS. Blood is collected from each pig before immunization of the vaccine, and blood is collected on 7 th day, 14 th day, 21 th day and 28 th day after immunization.

And (3) detecting related antibodies of the collected serum by using an A-type foot-and-mouth disease antibody ELISA detection kit. The result shows that the antibodies of all pigs are negative before the vaccine immunization, and the 14 th day after 1 immunization can reach more than 1: 128; the blank control group of pigs was negative for antibody and was unchanged. The specific results are shown in Table 5.

TABLE 5 type A foot-and-mouth disease ELISA antibody levels

And (3) detecting related antibodies of the collected serum by using an O-type foot-and-mouth disease SEA topological antibody ELISA detection kit. The result shows that the antibodies of all pigs in each immune group are negative before the vaccine immunization, and the 14 th day after 1 immunization can reach more than 1: 128; the blank control group of pigs was negative for antibody and was unchanged. The specific results are shown in Table 6.

TABLE 6 type O foot-and-mouth disease SEA topology ELISA antibody levels

The tests show that the A-type and O-type foot-and-mouth disease SEA topological type virus-like particle vaccine composition prepared by the invention can quickly form high-level specific antibodies and can play a good immune protection role in the A-type and O-type foot-and-mouth disease SEA topological types.

Example 8 foot-and-mouth disease type O CATHAY topology-like Virus particles

And (3) resuspending thalli expressing the O-type foot-and-mouth disease CATHAY topological virus protein antigen, and detecting by SDS-PAGE electrophoresis to show that three target proteins expressed in tandem in the supernatant are expressed. SDS-PAGE electrophoresis detection shows that the purified protein is purified and enriched.

The phosphotungstic acid negative staining and electron microscope observation show that the O-type foot-and-mouth disease CATHOY topological protein forms virus-like particles, and the formed virus-like particles are full, high in assembly efficiency and free of aggregation. The foot-and-mouth disease virus-like particles are placed at 4 ℃ for 3 months, and then phosphotungstic acid negative staining and electron microscope observation show that the virus-like particles are still full and have no aggregation phenomenon. It is demonstrated that the foot-and-mouth disease protein prepared by the sequence screened by the invention forms stable virus-like particles.

Example 9 preparation of bivalent aftosa virus-like particle vaccine composition type O (SEA topology, CATHAY topology), type A

The specific ratios of the components in the prepared vaccine are shown in table 7.

TABLE 7 ingredient ratio of bivalent foot-and-mouth disease virus-like particle vaccine composition of type O (SEA topology, CATHAY topology) and type A

Components	Vaccine 7	Vaccine 8	Vaccine 9	Vaccine 10	Vaccine 11
						Type A foot-and-mouth disease antigen (mu g/ml)	160	200	240	-	-
SEA topology type foot-and-mouth disease antigen (mu g/ml)	100	150	200	200	-
						CATHAY topology type foot-and-mouth disease antigen (mu g/ml)	100	150	200	-	200
Biphasic adjuvant (V/V%)	50％	50％	50％	50％	50％

Example 10 immunogenicity testing of bivalent foot-and-mouth disease Virus-like particle vaccine compositions type O (SEA topology, CATHAY topology), type A

Selecting 30 healthy susceptible frame pigs with negative A-type and O-type foot-and-mouth disease virus antigens and antibodies and weight of about 40kg, and randomly dividing the pigs into 6 groups with 5 heads each. 13-15 groups are vaccine 7, vaccine 8 and vaccine 9 immunization groups prepared in the embodiment 9 of the invention respectively, and the immunization route is neck intramuscular injection of 2 ml; 16-17 groups are vaccine 10 and vaccine 11 immunization groups prepared in the example 9 of the invention respectively, and the immunization route is neck intramuscular injection of 2 ml; group 18 was a blank control group and the immunization route was a neck intramuscular injection of 2ml PBS. Blood is collected from each pig before immunization of the vaccine, and blood is collected on 7 th day, 14 th day, 21 th day and 28 th day after immunization.

And (3) detecting related antibodies of the collected serum by using an A-type foot-and-mouth disease antibody ELISA detection kit. The results show that all the antibodies of the pigs before the vaccine immunization are negative, and the 14 th day after 1-time immunization of the 13 th group, the 14 th group and the 15 th group can reach more than 1: 128; the 16 th, 17 th and blank control groups of pigs were negative for antibody and unchanged. The specific results are shown in Table 8.

TABLE 8 type A foot-and-mouth disease ELISA antibody levels

And (3) detecting related antibodies of the collected serum by using an O-type foot-and-mouth disease SEA topological antibody ELISA detection kit. The results show that all the antibodies of the pigs before the vaccine immunization are negative, and the 14 th day after 1 immunization of the 13 th group, the 14 th group, the 15 th group and the 16 th group can reach more than 1: 128; the low-content immune group antibody level of the bivalent (three-component) foot-and-mouth disease virus-like particle vaccine composition still reaches or exceeds the high-content immune group antibody level of the monovalent O-type foot-and-mouth disease SEA topological virus-like particle vaccine composition; the 17 th and blank control group pigs were negative for antibody and did not change. Specific results are shown in Table 9; compared with the ELISA detection results of the type-O foot-and-mouth disease SEA topological antibodies in the groups 13, 14, 15 and 16, in the type-O (SEA, CATHAY) and type-A bivalent foot-and-mouth disease virus-like particle vaccine composition, a synergistic interaction effect is generated between two types of O antigens, so that the immune effect can be still ensured by halving the content of the type-O foot-and-mouth disease SEA topological virus-like particles.

TABLE 9 type O foot-and-mouth disease SEA topology ELISA antibody levels

And (3) detecting related antibodies of the collected serum by using an O-type foot-and-mouth disease CATHAY topological antibody ELISA detection kit. The results show that all the antibodies of the pigs before the vaccine immunization are negative, and the 14 th day after 1 immunization of the 13 th group, the 14 th group, the 15 th group and the 17 th group can reach more than 1: 128; the low-content immune group antibody level of the bivalent (three-component) foot-and-mouth disease virus-like particle vaccine composition still reaches or exceeds the high-content immune group antibody level of the monovalent O-type foot-and-mouth disease CATHOY topological type virus-like particle vaccine composition; the 16 th and blank control group pigs were negative for antibody and did not change. Specific results are shown in Table 10; compared with the ELISA detection results of the O-type foot-and-mouth disease CATHOY topological antibody in the groups 13, 14, 15 and 17, in the O-type (SEA topological type, CATHOY topological type) and A-type bivalent foot-and-mouth disease virus-like particle vaccine composition, a synergistic interaction effect is generated between two O-type antigens, so that the O-type foot-and-mouth disease CATHOY topological type virus-like particle antigen content is reduced by half, and the immune effect can be still ensured.

TABLE 10 type O foot-and-mouth disease CATHOY topology ELISA antibody levels

The experiment shows that the bivalent (three-component) foot-and-mouth disease virus-like particles prepared by the invention can quickly form high-level specific antibodies, the two O-type antigens are mutually synergistic, and the bivalent (three-component) foot-and-mouth disease virus-like particles can play a good immune protection role on the SEA topological type of the O-type foot-and-mouth disease and the CATHEY topological type of the O-type foot-and-mouth disease when the antigen content is halved; meanwhile, the monovalent O-type foot-and-mouth disease CATHAY topological virus-like particles are shown to play a good role in immunoreaction, and complete protection of pigs is realized.

Example 11 challenge protection test for bivalent aftosa-like particle vaccine compositions type O (SEA topology, CATHAY topology), type A

Selecting 34 healthy susceptible frame pigs with negative A-type and O-type foot-and-mouth disease virus antigens and antibodies and weight of about 40kg, and randomly dividing the pigs into 8 groups, 5 groups in 19 th to 23 th groups and 3 groups in 24 th to 26 th groups. Groups 19-21 are vaccine 8 immunization groups prepared in example 9 of the present invention, and the immunization route is neck intramuscular injection of 2 ml; the 22 th group to the 23 th group are commercial inactivated vaccine (Re-O/MYA98/JSCZ/2013 strain + Re-A/WH/09 strain) immunization groups, and the immunization route is neck intramuscular injection of 2 ml; groups 24-26 were controls and the immunization route was intramuscular injection of 2ml PBS into the neck. Clinical symptoms were observed in each group after immunization. After 28 days of immunization, each head is injected BY 1000ID50 virulent muscle, the virus strains attacked in the 19 th group, the 22 th group and the 24 th group are CATHAY topological type strains O/0718 strains, the virus strains attacked in the 20 th group, the 23 th group and the 25 th group are SEA topological type O/MYA98/BY/2010 strains, and the virus strains attacked in the 21 st group and the 26 th group are A type A/GDMM/2013 strains. After 10 days of observation, the disease is judged to be developed when at least 1 hoof of the pig is vesiculated or ulcerated. The disease onset and PD50 values are shown in tables 11, 12 and 13.

TABLE 11O/0718 strain challenge protection

TABLE 12O/MYA 98/BY/2010 Strain challenge protection

TABLE 13A/GDMM/2013 Strain challenge protection

The results show that the O-type (SEA topological type, CATHAY topological type) and A-type bivalent foot-and-mouth disease virus-like particle vaccine composition has good immune protection effect against the attack of O-type SEA topological type, O-type CATHAY topological type and A-type epidemic strains of the foot-and-mouth disease, and the PD50 is 13.59-15.59; the commercial inactivated vaccine can not completely protect against the attack of the foot-and-mouth disease O type SEA topological epidemic strain, and the PD50 is 7.19; the commercial inactivated vaccine can not effectively protect against the attack of O-type CATHAY topological epidemic strain of foot-and-mouth disease, and the PD50 is 2.01.

The O-type (SEA topological type, CATHAY topological type) and A-type bivalent foot-and-mouth disease virus-like particle vaccine composition has good immunogenicity, can resist the attack of epidemic strains, solves the problem that the existing inactivated vaccine can not effectively protect the epidemic strains, and has good biological safety.

Although the present invention has been described with reference to the preferred embodiments, it should be understood that various changes, substitutions and alterations can be made herein without departing from the spirit and scope of the invention as defined by the appended claims.

SEQUENCE LISTING

<110> Puleco bioengineering GmbH

<120> foot-and-mouth disease virus-like particle antigen, vaccine composition thereof, preparation method and application

<160> 10

<170> PatentIn version 3.3

<210> 1

<211> 654

<212> DNA

<213> type A foot-and-mouth disease virus

<400> 1

gacaaaaaaa ccgaagaaac caccctgctg gaagaccgta tcctgaccac ccgtaacggt 60

cacaccacct ctaccaccca gtcttctgtt ggtgttacct gcggttactc taccggtgaa 120

gaccacgttt ctggtccgaa cacctctggt ctggaaaccc gtgttgttca ggctgaacgt 180

ttcttcaaaa aacacctgtt cgactggacc accgacaaac cgttcggtca caccgaaaaa 240

ctggaactgc cgaccgaaca caaaggtgtt tacggtcagc tggttgaatc tttcgcttac 300

atgcgtaacg gttgggacgt tgaagtttct gctgttggta accagttcaa cggtggttgc 360

ctgctggttg ctatggttcc ggaattcaaa gaattcaccc agcgtgaaaa ataccagctg 420

accctgttcc cgcaccagtt catctctccg cgtaccaaca tgaccgctca catcaccgtt 480

ccgtacctgg gtgttaaccg ttacgaccag tacaaaaaac acaaaccgtg gaccctggtt 540

gttatggttg tttctccgct gaccacctct tctatcggtg ctacccagat caaagtttac 600

gctaacatcg ctccgaccca cgttcacgtt gctggtgaac tgccgtctaa agaa 654

<210> 2

<211> 663

<212> DNA

<213> type A foot-and-mouth disease virus

<400> 2

ggtatcgttc cggttgcttg ctctgacggt tacggtggtc tggttaccac cgacccgaaa 60

accgctgacc cggcttacgg tatggtttac aacccgccgc gtaccaacta cccgggtcgt 120

ttcaccaacc tgctggacgt tgctgaagct tgcccgacct tcctgtgctt cgacgacggt 180

aaaccgtaca tcgttacccg taccgacgaa cagcgtctgc tggctaaatt cgacctgtct 240

ctggctgcta aacacatgtc taacacctac ctgtctggta tcgctcagta ctacgctcag 300

tactctggta ccatcaacct gcacttcatg ttcaccggtt ctaccgactc taaagctcgt 360

tacatggttg cttacgttcc gccgggtgct gaaaccccgc cggacacccc ggaaaaagct 420

gctcactgca tccacgctga atgggacacc ggtctgaact ctaaattcac cttctctatc 480

ccgtacgttt ctgctgctga ctacgcttac accgcttctg acgaagctga aaccaccaac 540

gttcagggtt gggtttgcat ctaccagatc acccacggta aagctgaaca ggacaccctg 600

gttgtttctg tttctgctgg taaagacttc gaactgcgtc tgccgatcga cccgcgtgct 660

cag 663

<210> 3

<211> 636

<212> DNA

<213> type A foot-and-mouth disease virus

<400> 3

accaccgcta ccggtgaatc tgctgacccg gttaccacca ccgttgaaaa ctacggtggt 60

gaaacccagg ttcagcgtcg ttaccacacc gacgttggtt tcctgatgga ccgtttcgtt 120

cagatcaaac cggttggtcc gacccacgtt atcgacctga tgcagaccca ccagcacggt 180

ctggttggtg ctatgctgcg tgctgctacc tactacttct ctgacctgga aatcgttgtt 240

aaccacaccg gtaacctgac ctgggttccg aacggtgctc cggaagctgc tctgcagaac 300

acctctaacc cgaccgctta ccacaaagct ccgttcaccc gtctggctct gccgtacacc 360

gctccgcacc gtgttctggc taccgtttac tctggtacct ctaaatactc tgctccgcag 420

aaccgtcgtg gtgactctgg tccgctggct gctcgtctgg ctgctcagct gccggcttct 480

ttcaacttcg gtgctatccg tgctaccgaa atccgtgaac tgctggttcg tatgaaacgt 540

gctgaactgt actgcccgcg tccgctgctg gctgttgaag tttcttctca ggaccgtcac 600

aaacagaaaa tcatcgctcc ggctaaacag ctgctg 636

<210> 4

<211> 255

<212> DNA

<213> type O foot-and-mouth disease SEA topological virus

<400> 4

ggtgctggtc agtcttctcc ggctaccggt tctcagaacc agtctggtaa caccggttct 60

atcatcaaca actactacat gcagcagtac cagaactcta tggacaccca gctgggtgac 120

aacgctatct ctggtggttc taacgaaggt tctaccgaca ccacctctac ccacaccacc 180

aacacccaga acaacgactg gttctctaaa ctggcttctt ctgctttctc tggtctgttc 240

ggtgctctgc tggct 255

<210> 5

<211> 654

<212> DNA

<213> type O foot-and-mouth disease SEA topological virus

<400> 5

gacaaaaaaa ccgaagaaac caccctgctg gaagaccgta tcctgaccac ccgtaacggt 60

cacaccacct ctaccaccca gtcttctgtt ggtatcaccc acggttacgc taccgctgaa 120

gacttcgttt ctggtccgaa cacctctggt ctggaaaccc gtgttatcca ggctgaacgt 180

ttcttcaaaa cccacctgtt cgactgggtt acctctgacc cgttcggtcg ttaccacctg 240

ctggaactgc cgaccgacca caaaggtgtt tacggttctc tgaccgactc ttacgcttac 300

atgcgtaacg gttgggacgt tgaagttacc gctgttggta accagttcaa cggtggttgc 360

ctgctggttg ctatggttcc ggaactgtgc tctatcgaac gtcgtgaact gttccagctg 420

accctgttcc cgcaccagtt catcaacccg cgtaccaaca tgaccgctca catcaaagtt 480

ccgttcgttg gtgttaaccg ttacgaccag tacaaagttc acaaaccgtg gaccctggtt 540

gttatggttg ttgctccgct gaccgttaac accgaaggtg ctccgcagat caaagtttac 600

gctaacatcg ctccgaccaa cgttcacgtt gctggtgaat tcccgtctaa agaa 654

<210> 6

<211> 660

<212> DNA

<213> type O foot-and-mouth disease SEA topological virus

<400> 6

ggtatcttcc cggttgcttg ctctgacggt tacggtggtc tggttaccac cgacccgaaa 60

accgctgacc cggtttacgg taaagttttc aacccgccgc gtaacatgct gccgggtcgt 120

ttcaccaacc tgctggacgt tgctgaagct tgcccgacct tcctgcactt cgacggtgac 180

gttccgtacg ttaccaccaa aaccgactct gaccgtgttc tggctcagtt cgacctgtct 240

ctggctgcta aacacatgtc taacaccttc ctggctggtc tggctcagta ctacacccag 300

tactctggta ccatcaacct gcacttcatg ttcaccggtc cgaccgacgc taaagctcgt 360

tacatgatcg cttacgctcc gccgggtatg gaaccgccga aaaccccgga agctgctgct 420

cactgcatcc acgctgaatg ggacaccggt ctgaactcta aattcacctt ctctatcccg 480

tacctgtctg ctgctgacta cgcttacacc gcttctggtg ctgctgaaac caccaacgtt 540

cagggttggg tttgcctgtt ccagatcacc cacggtaaag ctgaaggtga cgctctggtt 600

gttctggctt ctgctggtaa agacttcgaa ctgcgtctgc cggttgacgc tcgtcagcag 660

<210> 7

<211> 639

<212> DNA

<213> type O foot-and-mouth disease SEA topological virus

<400> 7

accacctcta ccggtgaatc tgctgacccg gttaccgcta ccgttgaaaa ctacggtggt 60

gaaacccagg ttcagcgtcg tcaccacacc gacgtttctt tcatcctgga ccgtttcgtt 120

aaagttaccc cgaaagactc tatcaacgtt ctggacctga tgcagacccc gccgcacacc 180

ctggttggtg ctctgctgcg taccgctacc tactacttcg ctgacctgga agttgctgtt 240

aaacacaaag gtgacctgac ctgggttccg aacggtgctc cggaagctgc tctggacaac 300

accaccaacc cgaccgctta ccacaaagct ccgctgaccc gtctggctct gccgtacacc 360

gctccgcacc gtgttctggc taccgtttac aacggtaact gcaaatacgc tggtggttct 420

ctgccgaacg ttcgtggtga cctgcaggtt ctggctcaga aagctgcttg gccgctgccg 480

acctctttca actacggtgc tatcaaagct acccgtgtta ccgaactgct gtaccgtatg 540

aaacgtgctg aaacctactg cccgcgtccg ctgctggctg ttcacccgtc tgctgctcgt 600

cacaaacaga aaatcgttgc tccggttaaa cagtctctg 639

<210> 8

<211> 909

<212> DNA

<213> O type foot-and-mouth disease CATHAY topological virus

<400> 8

ggtgctggtc agtcttctcc gaccaccggt tctcagaacc agtctggtaa caccggttct 60

atcatcaaca actactacat gcagcagtac cagaactcta tggacaccca gctgggtgac 120

aacgctatct ctggtggttc taacgaaggt tctaccgaca ccacctctac ccacaccaac 180

aacacccaga acaacgactg gttctctaaa ctggctaaca ccgctttctc tggtctgttc 240

ggtgctctgc tggctgacaa aaaaaccgaa gaaaccaccc tgctggaaga ccgtatcctg 300

accacccgta acggtcacac cacctctacc acccagtctt ctgttggtgt tacctacggt 360

tacgctaccg ctgaagactt cgtttctggt ccgaacacct ctggtctgga aacccgtgtt 420

gttcaggctg aacgtttctt caaaacccac ctgttcgact ggggtaccaa cgactctttc 480

ggtcgttgcc acctgctgga actgccgacc gaccacaaag gtgtttacgg ttctctgacc 540

gactcttacg cttacatgcg taacggttgg gacgttgaag ttaccgctgt tggtaaccag 600

ttcaacggtg gttgcctgct ggttgctatg gttccggaac tgcgttctat caccaaacgt 660

gaactgtacc agctgaccct gttcccgcac cagttcatca acccgcgtac caacatgacc 720

gctcacatca ccgttccgta cctgggtgtt aaccgttacg accagtacaa agttcacaaa 780

ccgtggaccc tggttgttat ggttgttgct ccgctgaccg ttaacaacga aggtgctccg 840

cagatcaaag tttacgctaa catcgctccg accaacgttc acgttgctgg tgaactgccg 900

tctaaagaa 909

<210> 9

<211> 660

<212> DNA

<213> O type foot-and-mouth disease CATHAY topological virus

<400> 9

ggtatcttcc cggttgcttg ctctgacggt tacggtggtc tggttaccac cgacccgaaa 60

accgctgacc cggtttacgg taaagttttc aacccgccgc gtaacctgct gccgggtcgt 120

ttcaccaacc tgctggacgt tgctgaagct tgcccgacct tcctgcactt cgacggtgac 180

gttccgtacg ttgttaccaa aaccgactct gaccgtgttc tggctcagtt cgacctgtct 240

ctggctgcta aacacatgtc taacaccttc ctggctggtc tggctcagta ctacgctcag 300

tactctggta ccatcaacct gcacttcatg ttcaccggtc cgaccgacgc taaagctcgt 360

tacatggttg cttacgctcc gccgggtatg gaaccgccga aaaccccgga agctgctgct 420

cactgcatcc acgctgaatg ggacaccggt ctgaactcta aattcacctt ctctatcccg 480

tacctgtctg ctgctgacta cgcttacacc gcttctgacg ttgctgaaac caccaacgtt 540

cagggttggg tttgcctgtt ccagatcacc cacggtaaag ctgacggtga cgctctggtt 600

gttctggctt ctgctggtaa agacttcgac ctgcgtctgc cggttgacgc tcgtacccag 660

<210> 10

<211> 633

<212> DNA

<213> O type foot-and-mouth disease CATHAY topological virus

<400> 10

accacctctg ctggtgaatc tgctgacccg gttaccacca ccgttgaaaa ctacggtggt 60

gaaacccagg ttcagcgtcg tcagcacacc gacgttgctt tcatcctgga ccgtttcgtt 120

aaagttaaac cgcaggaaca ggttaacgtt ctggacctga tgcagatccc ggctcacacc 180

ctggttggtg ctctgctgcg taccgctacc tactacttct ctgacctgga actggctgtt 240

aaacacgaag gtgacctgac ctgggttccg aacggtgctc cggaaaccgc tctggacaac 300

accaccaacc cgaccgctta ccacaaagaa ccgctgaccc gtctggctct gccgtacacc 360

gctccgcacc gtgttctggc taccgtttac aacggttctt ctaaatacgg tgacgcttct 420

accaacaacg ttcgtggtga cctgcaggtt ctggttaaaa aagctgaacg tgctctgccg 480

acctctttca actacggtgc tatcaaagct gctcgtgtta ccgaactgct gtaccgtatg 540

aaacgtgctg aaacctactg cccgcgtccg ctgctggcta tccagccgtc taccgctcgt 600

cacaaacaga aaatcgttgc tccggctaaa cag 633